Multimodality Therapy for Thymic Carcinoma (TCA): Results of a 30-Year Single-Institution Experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 1, 2004, Pages 68-72

  Hernandez Ilizaliturri, Francisco J ^a   Tan, Dongfeng ^a   Cipolla, David ^a   Connolly, Gregory ^a   Debb, George ^a   Ramnath, Nithya ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anterior mediastinum; Multimodality therapy; Thymic carcinoma

Indexed keywords

CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; THYMIC CARCINOMA; THYMUS CANCER; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 0842305814     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000046301.83671.09     Document Type: Article

References (29)

1. Maggi G, Giaccone G, Donadio M, et al. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer 1986;58:765-76.
2. Snover DC, Levine GD, Rosai J. Thymic carcinoma. Five distinctive histological variants. Am J Surg Pathol 1982;6:451-70.
3. Wick MR, Scheithauer BW, Weiland LH, et al. Primary thymic carcinomas. Am J Surg Pathol 1982;6:613-30.
4. Truong LD, Mody DR, Cagle PT, et al. Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol 1990;14:151-66.
5. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92.
6. Bertnatz PE, Harrison EG, Clagett OT. Thymoma: clinicopathologic study. J Thorac Cardiovasc Surg 1961;42:424-44.
7. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115:303-38.
8. Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991;67:1025-32.
9. Koenigsberg RA, Greco D, Yatzi J, et al. Imaging and neurological manifestations of an unusual thymic carcinoma. Clin Imaging 2001;25:327-31.
10. Lucchi M, Mussi A, Ambrogi M, et al. Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol 2001;27:636-40.
11. Kamikubo Y, Shiiya N, Kubota S, et al. Thymic carcinoma with tumor thrombus into the superior vena cava. Jpn J Thorac Cardiovasc Surg 2001;49:327-9.
12. Carlson RW, Dorfman RF, Sikic BI. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer 1990;66:2092-4.
13. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91:2010-5.
14. Yano T, Hara N, Ichinose Y, et al. Treatment and prognosis of primary thymic carcinoma. J Surg Oncol 1993;52:255-8.
15. Geffen DB, Benharroch D, Yellin A, et al. Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation: report of a case with more than 4-year disease-free survival. Am J Clin Oncol 2001;24:566-9.
16. Loehrer PJ Sr, Wick MR. Thymic malignancies. Cancer Treat Res 2001;105:277-82.
17. Weide LG, Ulbright TM, Loehrer PJ Sr, et al. Thymic carcinoma: a distinct clinical entity responsive to chemotherapy. Cancer 1993;71:1219-23.
18. Dorfman DM, Shahsafaei A, Chan JK. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity. Am J Surg Pathol 1997;21:936-40.
19. Lequaglie C, Giudice G, Brega Massone PP, et al. Clinical and pathologic predictors of survival in patients with thymic tumors. J Cardiovasc Surg (Torino) 2002;43:269-74.
20. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an Intergroup study. N Engl J Med 1989;320:485-90.
21. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491-6.
22. Zambetti M, Valagussa P, Bonadonna G. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Ann Oncol 1996;7:481-5.
23. Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an Intergroup Study. J Clin Oncol 1998;16:3486-92.
24. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients With Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-55.
25. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
26. Vokes E, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-61.
27. Entwistle JWC III, Goldberg M. Multimodality therapy for resectable cancer of the thoracic esophagus. Ann Thorac Surg 2002;73:1009-15.
28. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-6.
29. Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002;25:266-8.